Status:
COMPLETED
Comparison of Oral Dexamethasone Doses in Asthma Exacerbation
Lead Sponsor:
Rady Children's Hospital, San Diego
Conditions:
Asthma
Reactive Airway Disease
Eligibility:
All Genders
2-17 years
Phase:
NA
Brief Summary
Hypothesis: A 2-day course of oral dexamethasone is the superior option for the resolution of symptoms and prevention of relapse in the emergency department (ED) management of mild-moderate asthma exa...
Detailed Description
Asthma has become a major public health problem of increasing concern in the US as it is the most prevalent chronic disease of childhood with over 6 million children under the age of 17 affected 7. Lo...
Eligibility Criteria
Inclusion
- children 2-17 years old
- with a history of wheezing (\> 1 episode requiring ß-2 agonist therapy) who present to the ED with mild to moderate asthma exacerbations
- \*mild-moderate exacerbations are defined as a RSS \< 11
- patients whose symptoms do not resolve after the first albuterol/atrovent treatment (given in the ED, or at home or via EMS within 1 hour prior to arrival to the ED) are eligible for enrollment
Exclusion
- age \< 2 years due to overlap with bronchiolitis
- use of steroids within 3 weeks
- recent exposure to TB, varicella, or herpes
- active varicella/herpes infections
- concomitant stridor, vomited 2 doses in ED
- severe asthma as defined by RSS \> 12
- requirement for or pre-existing IV access
- need for immediate airway protection
- history of intubations for asthma or comorbidities (Chronic Lung Disease (CLD), Congenital Heart Defects (CHD), or neurologic disorders)
Key Trial Info
Start Date :
August 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00942201
Start Date
August 1 2008
End Date
May 1 2009
Last Update
July 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rady Children's Hospital
San Diego, California, United States, 92123